Related content

Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade

By Tomkowski Witold  

Supportive Care in Cancer, Vol. 12, Iss. 1, 2004-01 ,pp. : 53-57

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients

By Yonemori Kan   Kunitoh Hideo   Tsuta Koji   Tamura Tetsutaro   Arai Yasuaki   Shimada Yasuhiro   Fujiwara Yasuhiro   Sasajima Yuko   Asamura Hisao   Tamura Tomohide  

Medical Oncology, Vol. 24, Iss. 4, 2007-12 ,pp. : 425-430

Humana Press, Inc

Access to resources Recommend Favorite

Weekly Low-doses with Prolonged Infusion of Gemcitabine /Cisplatin for Multi-treated Metastatic Breast Cancer Patients

By  

Current Cancer Therapy Reviews, Vol. 9, Iss. 2, 2013-05 ,pp. : 151-156

Bentham Science Publishers

Access to resources Recommend Favorite

Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment

By Maas K.W.   van der Lee I.   Bolt K.   Zanen P.   Lammers J.W.J.   Schramel F.M.N.H.  

Lung Cancer, Vol. 41, Iss. 3, 2003-09 ,pp. : 345-351

Elsevier

Access to resources Recommend Favorite

Characterization of IL-2-activated TILs and their use in intrapericardial immunotherapy in malignant pericardial effusion

By Toh Uhi   Fujii Teruhiko   Seki Naoko   Niiya Fumihiko   Shirouzu Kazuo   Yamana Hideaki  

Cancer Immunology, Immunotherapy, Vol. 55, Iss. 10, 2006-10 ,pp. : 1219-1227

Springer Publishing Company

Access to resources Recommend Favorite